Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$75.80 USD

75.80
1,189,837

+0.30 (0.40%)

Updated Jun 4, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias

by Zacks Equity Research

Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.

Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Centene (CNC), Cityblock Partner to Enhance Value-Based Care

by Zacks Equity Research

Centene (CNC) collaborates with Cityblock to provide comprehensive care services to Central Florida's Medicaid members.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on research and development raises optimism about the stock.

Boston Scientific (BSX) Rides on Emerging Markets, MedSurg

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Here's Why You Should Retain Inari Medical (NARI) for Now

by Zacks Equity Research

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Merit Medical's (MMSI) Latest Launch to Boost Patient Care

by Zacks Equity Research

Merit Medical's (MMSI) latest offering is likely to create an efficient approach to inflation, thereby providing improved patient care.

AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval

by Zacks Equity Research

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Reasons to Add HealthEquity (HQY) Stock to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

DaVita (DVA) Gains 34.5% YTD: What's Driving the Stock?

by Zacks Equity Research

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Three Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Philips' (PHG) Reports Positive AI-Powered Cardiac Study Data

by Zacks Equity Research

Philips' (PHG) AI-powered cardiac monitoring solutions demonstrate significantly lower re-admissions and a higher rate of survival in the retrospective study evaluating it in stroke patients.

Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.

Boston Scientific (BSX) mCRM System Study Outcome Favorable

by Zacks Equity Research

Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.

Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs

by Zacks Equity Research

Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.

AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft

by Zacks Equity Research

AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.

HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition

by Zacks Equity Research

HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.

Centene (CNC) to Continue Serving Kansas' Medicaid Members

by Zacks Equity Research

Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.

Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio

by Zacks Equity Research

Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy

by Zacks Equity Research

GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.

Urmimala Biswas headshot

3 Solid Buys From MedTech Following 2024 Guidance Raise

by Urmimala Biswas

Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.

Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?

by Zacks Equity Research

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts

by Zacks Equity Research

Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.